I-Mab to Present Givastomig Phase 1 Optimal Dose Estimation Data at SITC 2024

IMAB 10.30.2024

Full Press ReleaseSEC FilingsOur IMAB Tweets

About Gravity Analytica

Recent News

  • 01.08.2025 - I-Mab Announces Open Market Purchases of Company American Depositary Shares by Board Member
  • 01.06.2025 - I-Mab Announces Portfolio Prioritization of Givastomig (CLDN18.2 x 4-1BB Bispecific Antibody) as Lead Clinical Program
  • 12.04.2024 - Piper Sandler 36th Annual Healthcare Conference (In Person)

Recent Filings

  • 01.13.2025 - EX-99.1 EX-99.1
  • 01.13.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]

-Poster to be presented in a late-breaking abstract session at theSociety for Immunotherapy of Cancer(SITC) onSaturday, November 9, 2024

ROCKVILLE, Md.,Oct. 30, 2024/PRNewswire/ --I-Mab(NASDAQ: IMAB) (the "Company"), aU.S.-based, global biotech company exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced the presentation of a poster highlighting Phase 1 optimized dose estimation data for givastomig monotherapy (TJ033721/ABL111), a novel first-in-class Claudin18.2 (CLDN18.2) and 4-1BB bispecific antibody, at SITC 2024. The conference is being held inHouston, Texas, fromNovember 6-10, 2024.

(PRNewsfoto/I-Mab Biopharma)

Presentation Details:

  • Title: Optimal dose estimation using an integrated approach from Phase I data of givastomig, a novel Claudin18.2×4-1BB bispecific antibody
  • Poster#: 1474
  • Presenter:J.A. Yanez,I-Mab
  • Session: Poster Hall,George R. Brown Convention Center
  • Session Date:Saturday, November 9, 2024
  • Session Time:9:00 am CDT to 8:30 pm CDT, Level 1 –Exhibit Halls AB

A full copy of the poster will be available on theI-Mabwebsite under the "Innovation, Publications & Presentations" tab on November 9, 2024.

About Givastomig

Givastomig (TJ033721 / ABL111) is a bispecific antibody targeting Claudin (CLDN) 18.2-positive tumor cells. It conditionally activates T cells through the 4-1BB pathway in the tumor microenvironment where CLDN18.2 is expressed. Givastomig appears to maintain strong tumor binding and anti-tumor activity, attributable to a synergistic effect of proximal interaction with CLDN18.2 and 4-1BB, while minimizing liver toxicity and systemic immunotoxicity commonly seen with other emerging 4-1BB-based product candidates. InMarch 2022, theU.S. Food and Drug Administration(FDA) granted Orphan Drug Designation for givastomig for the treatment of gastric cancer, including cancer of the gastroesophageal junction. A Phase 1b study is ongoing evaluating givastomig, in combination with standard-of-care nivolumab plus chemotherapy, in treatment-naïve patients with gastric cancers, including gastroesophageal cancer (NCT04900818).

The program is being jointly developed through a global partnership with ABL Bio, in whichI-Mabis the lead party and shares worldwide rights, excludingChinaandSouth Korea, equally with ABL Bio.

About I-Mab

I-Mab(NASDAQ: IMAB) is aU.S.-based, global biotech company exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer.I-Mabhas established operations inRockville, Maryland, andShort Hills, New Jersey. For more information, please visithttps://www.i-mabbiopharma.comand follow us onLinkedInandX.

I-Mab Investor & Media Contacts

Tyler EhlerSenior Director, Investor RelationsIR@imabbio.com

CisionView original content to download multimedia:https://www.prnewswire.com/news-releases/i-mab-to-present-givastomig-phase-1-optimal-dose-estimation-data-at-sitc-2024-302290887.html

SOURCEI-Mab Biopharma

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com